DK3068775T3 - Substitueret piperidyl-ethyl-pyrimidin som ghrelin-o-acyl-transferase-inhibitor - Google Patents
Substitueret piperidyl-ethyl-pyrimidin som ghrelin-o-acyl-transferase-inhibitor Download PDFInfo
- Publication number
- DK3068775T3 DK3068775T3 DK14802755.0T DK14802755T DK3068775T3 DK 3068775 T3 DK3068775 T3 DK 3068775T3 DK 14802755 T DK14802755 T DK 14802755T DK 3068775 T3 DK3068775 T3 DK 3068775T3
- Authority
- DK
- Denmark
- Prior art keywords
- ghrelin
- ethyl
- compound
- add
- mmol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Forbindelse med formel
eller et farmaceutisk acceptabelt salt deraf.
2. Forbindelse ifølge krav 1 med formel
eller et farmaceutisk acceptabelt salt deraf.
3. Forbindelse ifølge et hvilket som helst af kravene 1 eller 2 med formel
4. Farmaceutisk sammensætning omfattende en forbindelse ifølge et hvilket som helst af kravene 1 til 3 eller et farmaceutisk acceptabelt salt deraf og et eller flere farmaceutisk acceptable bærestoffer, fortyndingsmidler eller hjælpestoffer.
5. Farmaceutisk sammensætning ifølge krav 4 omfattende et eller flere andre terapeutiske midler.
6. Forbindelse ifølge et hvilket som helst af kravene 1 til 3 eller et farmaceutisk acceptabelt salt deraf til anvendelse i terapi.
7. Forbindelse ifølge et hvilket som helst af kravene 1 til 3 eller et farmaceutisk acceptabelt salt deraf til anvendelse ved reduktion af vægtøgning.
8. Forbindelse ifølge et hvilket som helst af kravene 1 til 3 eller et farmaceutisk acceptabelt salt deraf til anvendelse ved reduktion af ny vægtøgning.
9. Forbindelse ifølge et hvilket som helst af kravene 1 til 3 eller et farmaceutisk acceptabelt salt deraf til anvendelse ved behandling af obesitas.
10. Forbindelse ifølge et hvilket som helst af kravene 1 til 3 eller et farmaceutisk acceptabelt salt deraf til anvendelse ved behandling af type 2-diabetes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382460 | 2013-11-14 | ||
| PCT/US2014/064202 WO2015073281A1 (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3068775T3 true DK3068775T3 (da) | 2017-10-23 |
Family
ID=49622771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14802755.0T DK3068775T3 (da) | 2013-11-14 | 2014-11-06 | Substitueret piperidyl-ethyl-pyrimidin som ghrelin-o-acyl-transferase-inhibitor |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US9035051B1 (da) |
| EP (1) | EP3068775B1 (da) |
| JP (1) | JP6159484B2 (da) |
| KR (1) | KR101739243B1 (da) |
| CN (1) | CN105636948B (da) |
| AP (1) | AP2016009189A0 (da) |
| AR (1) | AR098274A1 (da) |
| AU (1) | AU2014348967B2 (da) |
| BR (1) | BR112016009488B1 (da) |
| CA (1) | CA2926224C (da) |
| CL (1) | CL2016001023A1 (da) |
| CR (1) | CR20160184A (da) |
| CY (1) | CY1119489T1 (da) |
| DK (1) | DK3068775T3 (da) |
| DO (1) | DOP2016000070A (da) |
| EA (1) | EA028550B1 (da) |
| ES (1) | ES2647790T3 (da) |
| HK (1) | HK1222860A1 (da) |
| HR (1) | HRP20171648T1 (da) |
| HU (1) | HUE035590T2 (da) |
| IL (1) | IL244856A (da) |
| JO (1) | JO3302B1 (da) |
| LT (1) | LT3068775T (da) |
| MA (1) | MA39025B1 (da) |
| ME (1) | ME02841B (da) |
| MX (1) | MX2016006223A (da) |
| NO (1) | NO3068775T3 (da) |
| NZ (1) | NZ718373A (da) |
| PE (1) | PE20160609A1 (da) |
| PH (1) | PH12016500895B1 (da) |
| PL (1) | PL3068775T3 (da) |
| PT (1) | PT3068775T (da) |
| RS (1) | RS56533B1 (da) |
| SG (1) | SG11201602953YA (da) |
| SI (1) | SI3068775T1 (da) |
| TN (1) | TN2016000145A1 (da) |
| TW (1) | TWI538677B (da) |
| UA (1) | UA118034C2 (da) |
| WO (1) | WO2015073281A1 (da) |
| ZA (1) | ZA201602202B (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104672A1 (es) * | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AR104673A1 (es) * | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| PT3494120T (pt) * | 2016-08-05 | 2021-05-26 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina para utilização como inibidores de grelina o-acil transferase (goat) |
| CN106478519B (zh) * | 2016-10-10 | 2018-12-11 | 上海再启生物技术有限公司 | 一种2-甲基-4-氨基-6-氯嘧啶的制备方法 |
| KR20200118124A (ko) | 2018-02-02 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 그렐린 o-아실 트랜스퍼라제(goat) 억제제로 사용하기 위한 헤테로사이클릴-치환된 옥사디아졸로피리딘 유도체 |
| EP3746443B1 (en) * | 2018-02-02 | 2022-07-06 | Boehringer Ingelheim International GmbH | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| CN111655700B (zh) | 2018-02-02 | 2023-07-18 | 勃林格殷格翰国际有限公司 | 作为饥饿素o-酰基转移酶(goat)抑制剂的噁二唑并吡啶衍生物 |
| JP7225253B2 (ja) | 2018-02-02 | 2023-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体 |
| CN108558849A (zh) * | 2018-05-30 | 2018-09-21 | 王丽萍 | 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用 |
| CN108516971A (zh) * | 2018-05-30 | 2018-09-11 | 王丽萍 | 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用 |
| CN108774221A (zh) * | 2018-05-30 | 2018-11-09 | 王丽萍 | 一种goat抑制剂及其在肥胖和糖尿病中的应用 |
| CN108610337A (zh) * | 2018-05-30 | 2018-10-02 | 王丽萍 | 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用 |
| CN108558852A (zh) * | 2018-05-30 | 2018-09-21 | 王丽萍 | 一种goat抑制剂及其在肥胖和糖尿病中的应用 |
| WO2021233884A1 (en) | 2020-05-22 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
| WO2021233882A1 (en) | 2020-05-22 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4929601A (en) * | 2000-03-23 | 2001-10-03 | Merck & Co Inc | Substituted piperidines as melanocortin receptor agonists |
| US20060233788A1 (en) | 2003-09-05 | 2006-10-19 | Heiman Mark L | Anti-ghrelin antibodies |
| JP2008515771A (ja) | 2004-07-14 | 2008-05-15 | イーライ リリー アンド カンパニー | 抗グレリン抗体 |
| EP1814916A2 (en) | 2004-11-15 | 2007-08-08 | Eli Lilly And Company | Desacyl ghrelin antibodies and therapeutic uses thereof |
| WO2006079239A1 (en) | 2005-01-26 | 2006-08-03 | Kistler Holding Ag | Ground insulated piezoelectric sensor for the measurement of acceleration or pressure |
| EP1856154A1 (en) | 2005-02-23 | 2007-11-21 | Eli Lilly And Company | Humanized anti-ghrelin antibodies |
| CN101175759A (zh) * | 2005-05-17 | 2008-05-07 | 先灵公司 | 作为治疗血脂异常的烟酸受体激动剂的杂环化合物 |
| US7723342B2 (en) * | 2005-05-17 | 2010-05-25 | Schering Corporation | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia |
| US20070213359A1 (en) * | 2005-12-30 | 2007-09-13 | Acadia Pharmaceuticals Inc. | Bicyclic-nitrogen compounds as modulators of ghrelin receptor and uses thereof |
| JP2011518774A (ja) * | 2008-03-20 | 2011-06-30 | フォレスト・ラボラトリーズ・ホールディングス・リミテッド | ステアロイル−ＣｏＡデサチュラーゼの阻害剤としての新規ピペリジン誘導体 |
| AR091516A1 (es) * | 2012-06-22 | 2015-02-11 | Actelion Pharmaceuticals Ltd | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida |
-
2014
- 2014-06-11 UA UAA201604765A patent/UA118034C2/uk unknown
- 2014-10-30 JO JOP/2014/0316A patent/JO3302B1/ar active
- 2014-10-31 TW TW103137938A patent/TWI538677B/zh active
- 2014-11-03 AR ARP140104111A patent/AR098274A1/es unknown
- 2014-11-06 KR KR1020167012340A patent/KR101739243B1/ko active IP Right Grant
- 2014-11-06 PT PT148027550T patent/PT3068775T/pt unknown
- 2014-11-06 BR BR112016009488-3A patent/BR112016009488B1/pt active IP Right Grant
- 2014-11-06 CN CN201480058584.6A patent/CN105636948B/zh active Active
- 2014-11-06 PE PE2016000620A patent/PE20160609A1/es active IP Right Grant
- 2014-11-06 LT LTEP14802755.0T patent/LT3068775T/lt unknown
- 2014-11-06 PL PL14802755T patent/PL3068775T3/pl unknown
- 2014-11-06 NO NO14802755A patent/NO3068775T3/no unknown
- 2014-11-06 US US14/534,212 patent/US9035051B1/en active Active
- 2014-11-06 TN TN2016000145A patent/TN2016000145A1/en unknown
- 2014-11-06 SG SG11201602953YA patent/SG11201602953YA/en unknown
- 2014-11-06 NZ NZ718373A patent/NZ718373A/en unknown
- 2014-11-06 SI SI201430379T patent/SI3068775T1/sl unknown
- 2014-11-06 MX MX2016006223A patent/MX2016006223A/es active IP Right Grant
- 2014-11-06 AP AP2016009189A patent/AP2016009189A0/en unknown
- 2014-11-06 RS RS20171067A patent/RS56533B1/sr unknown
- 2014-11-06 EA EA201690764A patent/EA028550B1/ru not_active IP Right Cessation
- 2014-11-06 ES ES14802755.0T patent/ES2647790T3/es active Active
- 2014-11-06 ME MEP-2017-224A patent/ME02841B/me unknown
- 2014-11-06 HU HUE14802755A patent/HUE035590T2/en unknown
- 2014-11-06 DK DK14802755.0T patent/DK3068775T3/da active
- 2014-11-06 EP EP14802755.0A patent/EP3068775B1/en active Active
- 2014-11-06 WO PCT/US2014/064202 patent/WO2015073281A1/en active Application Filing
- 2014-11-06 MA MA39025A patent/MA39025B1/fr unknown
- 2014-11-06 JP JP2016531705A patent/JP6159484B2/ja active Active
- 2014-11-06 AU AU2014348967A patent/AU2014348967B2/en active Active
- 2014-11-06 CA CA2926224A patent/CA2926224C/en active Active
-
2016
- 2016-03-29 DO DO2016000070A patent/DOP2016000070A/es unknown
- 2016-04-03 IL IL244856A patent/IL244856A/en active IP Right Grant
- 2016-04-04 ZA ZA201602202A patent/ZA201602202B/en unknown
- 2016-04-21 CR CR20160184A patent/CR20160184A/es unknown
- 2016-04-29 CL CL2016001023A patent/CL2016001023A1/es unknown
- 2016-05-13 PH PH12016500895A patent/PH12016500895B1/en unknown
- 2016-09-22 HK HK16111132.8A patent/HK1222860A1/zh unknown
-
2017
- 2017-10-20 CY CY20171101093T patent/CY1119489T1/el unknown
- 2017-10-27 HR HRP20171648TT patent/HRP20171648T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3068775T3 (da) | Substitueret piperidyl-ethyl-pyrimidin som ghrelin-o-acyl-transferase-inhibitor | |
| JP6941147B2 (ja) | アリール受容体モジュレーターならびにその作製および使用方法 | |
| AU2018201896B2 (en) | Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor | |
| EP3283473B1 (en) | Ghrelin o-acyl transferase inhibitors | |
| EP3283474B1 (en) | Ghrelin o-acyl transferase inhibitors |